Flash Finance

Indoco Remedies LimitedINDOCOCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹245.65
MCap ₹2,264 Cr · P/E 21.6
Indoco Remedies Limited — Stock analysis & AI research Indoco Remedies Limited — Seasonality — best & worst months Indoco Remedies Limited — Technical indicators & charts Indoco Remedies Limited — Technical setup — score, trend, support & resistance Indoco Remedies Limited — Live exchange announcements
📈 Bullish EMA Alignment📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹409 Cr
Sales · Jun 2026
+4.2% YoY
₹42 Cr
Operating Profit · Jun 2026
+184.6% YoY
10.3%
OPM % · Jun 2026
+171.1% YoY
₹82 Cr
Net Profit · Jun 2026
+393.4% YoY
₹8.92
EPS · Jun 2026
+393.4% YoY

📝 Indoco Remedies Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Indoco Remedies Limited reported revenue of ₹409 crore for the quarter ended June 2026 (Q1 FY27), up 4.2% from ₹393 crore in the same quarter last year, and down 8.9% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹82 crore from a net loss of ₹28 crore a year earlier. Earnings per share (EPS) came in at ₹8.92.

Operating profit stood at ₹42 crore — an operating margin (OPM) of 10.3%, compared with 3.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Indoco Remedies Limited posted revenue of ₹1,684 crore, a growth of 10.9% over FY25, with a net loss of ₹6 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,701 crore with a net profit of ₹105 crore.

Valuation snapshot

At the current price of ₹245.65, INDOCO has a market capitalisation of ₹2,264 crore and a trailing P/E of about 21.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 20th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 58.86%, foreign institutional investors (FIIs) 0.94%, domestic institutional investors (DIIs) 18.15%, public shareholders 21.90% of Indoco Remedies Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,264 Cr
Current Price ?
₹245.7
P/E ?
21.62below ind
Industry P/E ?
37.20
P/B ?
2.06
P/S ?
1.33
P/FCF ?
15.62
Enterprise Value ?
₹3,024 Cr
EV/EBITDA ?
16.39
PEG ?
N/A
Earnings Yield ?
2.5%
Dividend Yield ?
0.08%
Profitability & Returns
Sales (TTM) ?
₹1,701 Cr
OPM ?
10.9%
Profit after tax (TTM) ?
₹105 Cr
EPS (TTM) ?
₹11.36
ROCE ?
4.0%
ROE ?
9.5%
ROA ?
4.4%
Growth
Sales — latest qtr ?
₹409 Cr
PAT — latest qtr ?
₹82 Cr
YoY qtr sales growth ?
4.2%
YoY qtr profit growth ?
393.4%
Sales growth (3y) ?
0%
Sales growth (5y) ?
6%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹760 Cr
Debt to Equity ?
0.69
Interest Coverage ?
0.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
58.86%
Change in promoter holding ?
-0.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-0.7%
Return 6 months ?
11.9%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 427423473449445401397373347393442401449409 +4.2% -8.9%
Operating Profit 646372655752532031553266342 +184.6% -33.0%
Other Income 001344446677104 -19.9% -56.8%
Interest 9881011121514162422202323 -3.6% +0.1%
Depreciation 1820212324242525252528272728 +11.3% +5.0%
Profit Before Tax 38364427462017-13-31-2810-202893 +428.2% +237.5%
Net Profit 25263320381513-10-26-2815-202782 +393.4% +201.0%
EPS 2.752.813.602.174.081.621.39-1.11-2.85-3.041.63-2.172.968.92 +393.4% +201.4%
OPM % 15.0% 14.9% 15.3% 14.5% 12.9% 12.8% 13.3% 5.4% 1.0% 3.8% 12.1% 6.5% 14.0% 10.3% +171.1% -26.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,518 Cr ₹1,684 Cr ₹1,701 Cr +10.9%
Operating Profit ₹128 Cr ₹157 Cr ₹185 Cr +22.7%
OPM % 8.43% 9.33% 10.85% +10.7%
NPM % -0.58% -0.34% 6.16% +41.4%
Other Income ₹18 Cr ₹30 Cr ₹29 Cr +60.4%
Depreciation ₹98 Cr ₹107 Cr ₹110 Cr +8.8%
Interest ₹57 Cr ₹88 Cr ₹88 Cr +56.3%
EBIT ₹30 Cr ₹50 Cr ₹75 Cr +68.7%
PBT ₹-7 Cr ₹-11 Cr ₹110 Cr -55.6%
Tax ₹1 Cr ₹-6 Cr ₹5 Cr -527.2%
Net Profit ₹-9 Cr ₹-6 Cr ₹105 Cr +35.2%
EPS ₹-0.95 ₹-0.62 ₹11.34 +34.7%
Material Cost ₹476 Cr ₹493 Cr ₹492 Cr +3.7%
Employee Cost ₹369 Cr ₹394 Cr ₹386 Cr +6.8%
Extraordinary Items ₹1 Cr ₹-3 Cr ₹94 Cr -388.9%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 18181818 +0.0%
Reserves 1,0091,1081,0851,081 -0.4%
Borrowings 333514754760 +0.8%
Other Liabilities 300320344506 +47.1%
Total Liabilities 1,6601,9612,2012,365 +7.5%
Fixed Assets 661732754913 +21.1%
CWIP 11311422623 -89.8%
Investments 205952160 +207.7%
Other Assets 8661,0551,1691,269 +8.6%
Total Assets 1,6601,9612,2012,365 +7.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 17917791226 +148.4%
Cash from Investing Activity -209-302-260-87 +66.5%
Cash from Financing Activity 23122169-133 -178.7%
Net Cash Flow -7-3-06 —
Free Cash Flow -9-1-164145 +188.4%
CFO/OP 84%80%83%148% +78.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 778390117 +30.0%
Inventory Days 228207299235 -21.4%
Days Payable 8979121190 +57.0%
Cash Conversion Cycle 217211267162 -39.3%
Working Capital Days 81646047 -21.7%
ROCE % 17%12%3%4% +33.3%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 58.90%58.90%58.90%58.86% -0.1%
FIIs 1.22%1.25%1.10%0.94% -14.5%
DIIs 18.96%18.16%18.15%18.15% +0.0%
Public 20.82%21.60%21.76%21.90% +0.6%
Others 0.09%0.09%0.09%0.14% +55.6%
No. of Shareholders 33,12933,31932,65932,276 -1.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Indoco Remedies Limited's revenue in Q1 FY27?
Indoco Remedies Limited reported revenue of ₹409 crore for the quarter ended June 2026 (Q1 FY27), up 4.2% from ₹393 crore in the same quarter last year, and down 8.9% sequentially over the March 2026 quarter.
What was Indoco Remedies Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹82 crore from a net loss of ₹28 crore a year earlier. Earnings per share (EPS) came in at ₹8.92.
What is INDOCO's market capitalisation and P/E ratio?
At the current price of ₹245.65, INDOCO has a market capitalisation of ₹2,264 crore and a trailing P/E of about 21.6.
Who owns Indoco Remedies Limited? (shareholding pattern)
As of Mar 2026, promoters held 58.86%, foreign institutional investors (FIIs) 0.94%, domestic institutional investors (DIIs) 18.15%, public shareholders 21.90% of Indoco Remedies Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI